US Stock Market Move | Eli Lilly (LLY.US) rose over 7%, with Q2 revenue increasing by 48% year-on-year, and has raised its full-year performance outlook.

On Wednesday, Eli Lilly (LLY.US) rose more than 7% to $1197.12. In terms of news, on August 5th, Eli Lilly announced its Q2 2026 financial report. The company achieved revenue of $22.97 billion, a year-over-year increase of 48%, surpassing market expectations of $20.59 billion; the adjusted earnings per share (Non-GAAP EPS) reached $8.38, a year-over-year increase of 33%, far exceeding analysts' expectations of $6.31. The company's net profit was $7.1 billion, compared to $5.66 billion in the same period last year. Due to acquisition-related expenses, the GAAP earnings per share during the reporting period was $7.94, which included transaction-related expenses of $3.03 per share; after excluding one-time factors like adjustments for intangible asset values, the adjusted earnings per share reached $8.38. Eli Lilly further raised its full-year guidance, projecting that revenue for the entire year of 2026 would be between $85 billion and $87 billion, higher than the previous forecast of $82 billion to $85 billion. The company expects adjusted earnings per share for the full year to be between $35.50 and $36.50. Eli Lilly stated that despite transaction-related expenses weighing down the annual profit by about $3.03 per share, the company has increased its base earnings expectations by about $2.78 per share, reflecting strong momentum in core business growth.